Streptokinase 750,000unit powder for solution for infusion vials
Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Streptokinase
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Streptokinase
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Streptokinase on the MHRA register
Biofactor Streptokinase 750,000unit powder for solution for infusion vials
WHO defined daily dose (DDD)
1.5 mega unit
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)
Coronary revascularisation: Cangrelor (ESNM63)
PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (HTG282)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 25 · 1971–2025
Showing the 50 most relevant studies, sorted by most relevant.
J. O'Meara, R. Mcnutt, A. Evans, et al.
The New England journal of medicine, 1994
Journal of the American College of Cardiology, 1988
L. Bolognese
The Lancet, 1988
Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.
The Lancet, 1990
J. Kennedy, J. Ritchie, K. Davis, et al.
The New England journal of medicine, 1983
M. Verstraete, M. Bory, D. Collen, et al.
The Lancet, 1985
C. Jerjes-Sánchez, A. Ramírez-Rivera, María García, et al.
Journal of Thrombosis and Thrombolysis, 2005
Jeffrey L. Anderson, H. Marshall, B. Bray, et al.
The New England journal of medicine, 1983
W. O'neill, G. Timmis, P. Bourdillon, et al.
The New England journal of medicine, 1986
J. Kennedy, J. Ritchie, K. Davis, et al.
The New England journal of medicine, 1985
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
133 found
Half-life
Not available
Mechanism
Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 921 interactions
Proteins and enzymes this drug interacts with in the body
PMID:6447255
Cleavage of fibronectin and laminin leads to cell detachment and apoptosis.
Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells
PMID:1672265 PMID:8136362
The thrombin-activated receptor signaling pathway is mediated through PTX-insensitive G proteins, activation of phospholipase C resulting in the production of 1D-myo-inositol 1,4,5-trisphosphate (InsP3) which binds to InsP3 receptors causing calcium release from the stores (By similarity). In astrocytes, the calcium released into the cytosol allows the Ca(2+)-dependent release of L-glutamate into the synaptic cleft through BEST1, that targets the neuronal postsynaptic GRIN2A/NMDAR receptor resulting in the synaptic plasticity regulation (By similarity). May play a role in platelets activation and in vascular development .
PMID:10079109
Mediates up-regulation of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, triggered by coagulation factor Xa (F10) in cardiac fibroblasts and umbilical vein endothelial cells PMID:30568593 PMID:34831181
Enzymes involved in drug metabolism — important for understanding drug interactions
Involved compounds
ATC B01AD01
ATC B06AA55
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Streptokinase
Additional database identifiers
Drugs Product Database (DPD)
5991
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9071
GenAtlas
PLG
GeneCards
PLG
GenBank Gene Database
X05199
GenBank Protein Database
387026
Guide to Pharmacology
2394
UniProt Accession
PLMN_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3537
GenAtlas
F2R
GeneCards
F2R
GenBank Gene Database
M62424
GenBank Protein Database
339677
Guide to Pharmacology
347
UniProt Accession
PAR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9035
GenAtlas
PLA2G4A
GeneCards
PLA2G4A
GenBank Gene Database
M72393
GenBank Protein Database
190007
Guide to Pharmacology
1424
UniProt Accession
PA24A_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q416485), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.